JP2016539083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539083A5 JP2016539083A5 JP2016519326A JP2016519326A JP2016539083A5 JP 2016539083 A5 JP2016539083 A5 JP 2016539083A5 JP 2016519326 A JP2016519326 A JP 2016519326A JP 2016519326 A JP2016519326 A JP 2016519326A JP 2016539083 A5 JP2016539083 A5 JP 2016539083A5
- Authority
- JP
- Japan
- Prior art keywords
- αvβ6
- her2
- inhibitor
- binding agent
- targeted binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 121
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 99
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 99
- 239000011230 binding agent Substances 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 48
- 239000003112 inhibitor Substances 0.000 claims description 41
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 32
- 206010006187 Breast cancer Diseases 0.000 claims description 27
- 208000026310 Breast neoplasm Diseases 0.000 claims description 27
- -1 forfilinox Chemical compound 0.000 claims description 25
- 230000005764 inhibitory process Effects 0.000 claims description 23
- 229960000575 trastuzumab Drugs 0.000 claims description 23
- 210000004881 tumor cell Anatomy 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 22
- 229940124647 MEK inhibitor Drugs 0.000 claims description 16
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 16
- 229910052697 platinum Inorganic materials 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 239000013610 patient sample Substances 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 9
- UAXHPOBBKRWJGA-ZDUSSCGKSA-N 2-[2-[(2s)-2-methyl-2,3-dihydroindol-1-yl]-2-oxoethyl]-6-morpholin-4-yl-1h-pyrimidin-4-one Chemical compound C([C@@H]1C)C2=CC=CC=C2N1C(=O)CC(NC(=O)C=1)=NC=1N1CCOCC1 UAXHPOBBKRWJGA-ZDUSSCGKSA-N 0.000 claims description 8
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 claims description 8
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims description 8
- LMJFJIDLEAWOQJ-CQSZACIVSA-N 8-[(1r)-1-(3,5-difluoroanilino)ethyl]-n,n-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide Chemical compound N([C@H](C)C=1C2=C(C(C=C(O2)N2CCOCC2)=O)C=C(C=1)C(=O)N(C)C)C1=CC(F)=CC(F)=C1 LMJFJIDLEAWOQJ-CQSZACIVSA-N 0.000 claims description 8
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 8
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 8
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 8
- 229940125497 HER2 kinase inhibitor Drugs 0.000 claims description 8
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 8
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 8
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 8
- 239000012828 PI3K inhibitor Substances 0.000 claims description 8
- 229940124607 PI3Kα inhibitor Drugs 0.000 claims description 8
- 229940125520 PI3Kβ inhibitor Drugs 0.000 claims description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 8
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 8
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims description 8
- 229940028652 abraxane Drugs 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 230000005779 cell damage Effects 0.000 claims description 8
- 208000037887 cell injury Diseases 0.000 claims description 8
- 229960005395 cetuximab Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- 229940121647 egfr inhibitor Drugs 0.000 claims description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 8
- 229960001433 erlotinib Drugs 0.000 claims description 8
- 229960005167 everolimus Drugs 0.000 claims description 8
- 229960002949 fluorouracil Drugs 0.000 claims description 8
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 8
- 229960002584 gefitinib Drugs 0.000 claims description 8
- 229960005277 gemcitabine Drugs 0.000 claims description 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 8
- 229940022353 herceptin Drugs 0.000 claims description 8
- 229960003278 osimertinib Drugs 0.000 claims description 8
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 8
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 8
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 8
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims description 8
- 229950010746 selumetinib Drugs 0.000 claims description 8
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- 229960004066 trametinib Drugs 0.000 claims description 8
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 101150107888 AKT2 gene Proteins 0.000 claims description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 229910052758 niobium Inorganic materials 0.000 claims 1
- 239000010955 niobium Substances 0.000 claims 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 description 17
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 11
- 238000010186 staining Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 108091007505 ADAM17 Proteins 0.000 description 2
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 101001015064 Homo sapiens Integrin beta-6 Proteins 0.000 description 1
- 102100033011 Integrin beta-6 Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885302P | 2013-10-01 | 2013-10-01 | |
| US61/885,302 | 2013-10-01 | ||
| PCT/EP2014/071028 WO2015049280A1 (en) | 2013-10-01 | 2014-10-01 | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019052035A Division JP2019142876A (ja) | 2013-10-01 | 2019-03-20 | αＶβ６を過剰発現する癌を治療及び診断する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539083A JP2016539083A (ja) | 2016-12-15 |
| JP2016539083A5 true JP2016539083A5 (cg-RX-API-DMAC7.html) | 2017-11-09 |
| JP6527508B2 JP6527508B2 (ja) | 2019-06-05 |
Family
ID=51655742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519326A Active JP6527508B2 (ja) | 2013-10-01 | 2014-10-01 | αＶβ６を過剰発現する癌を治療及び診断する方法 |
| JP2019052035A Pending JP2019142876A (ja) | 2013-10-01 | 2019-03-20 | αＶβ６を過剰発現する癌を治療及び診断する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019052035A Pending JP2019142876A (ja) | 2013-10-01 | 2019-03-20 | αＶβ６を過剰発現する癌を治療及び診断する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160319032A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3052523B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6527508B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106232625B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014331118B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2925057A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015049280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| JP7107839B2 (ja) * | 2015-12-11 | 2022-07-27 | ルプレヒト－カールス－ウニベルジテート ハイデルベルク | Ｐｋｍ２モジュレーター及びｈｍｇｂ１の組合せ製剤 |
| JP7030066B2 (ja) | 2016-05-26 | 2022-03-04 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｅｇｆｒ阻害剤化合物 |
| TWI802193B (zh) * | 2016-06-14 | 2023-05-11 | 美商默沙東有限責任公司 | 抗凝血因子ｘｉ抗體 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN106950371B (zh) * | 2017-02-17 | 2019-03-08 | 张灏 | Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途 |
| JP2020512978A (ja) * | 2017-03-31 | 2020-04-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US20220211783A1 (en) * | 2019-02-22 | 2022-07-07 | Candel Therapeutics, Inc. | Gmci and ddri combination therapy for treating cancer |
| IL293195A (en) | 2019-12-05 | 2022-07-01 | Seagen Inc | Anti-avb6 antibodies and antibody-drug conjugates |
| CN114195893A (zh) * | 2020-09-17 | 2022-03-18 | 百奥泰生物制药股份有限公司 | 抗整联蛋白抗体或抗原结合片段及其应用 |
| CN117603348B (zh) * | 2023-11-24 | 2024-08-09 | 优睿赛思(武汉)生物科技有限公司 | 抗新型冠状病毒s蛋白的全人源化抗体及其应用 |
| EP4595981A1 (en) * | 2024-02-01 | 2025-08-06 | Jack Elands | Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody |
| WO2025163120A1 (en) | 2024-02-01 | 2025-08-07 | Adcytherix Sas | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0308585B8 (pt) * | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| CA2658612C (en) * | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
| MX360141B (es) * | 2012-02-17 | 2018-10-24 | Seattle Genetics Inc | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. |
-
2014
- 2014-10-01 WO PCT/EP2014/071028 patent/WO2015049280A1/en not_active Ceased
- 2014-10-01 EP EP14777632.2A patent/EP3052523B1/en not_active Not-in-force
- 2014-10-01 CA CA2925057A patent/CA2925057A1/en not_active Abandoned
- 2014-10-01 CN CN201480065738.4A patent/CN106232625B/zh active Active
- 2014-10-01 JP JP2016519326A patent/JP6527508B2/ja active Active
- 2014-10-01 AU AU2014331118A patent/AU2014331118B2/en active Active
- 2014-10-01 US US15/026,350 patent/US20160319032A1/en not_active Abandoned
-
2018
- 2018-11-06 US US16/181,907 patent/US20190389967A1/en not_active Abandoned
-
2019
- 2019-03-20 JP JP2019052035A patent/JP2019142876A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539083A5 (cg-RX-API-DMAC7.html) | ||
| Ahcene Djaballah et al. | HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target | |
| JP7325463B2 (ja) | がんの予後診断及び治療のための方法及び組成物 | |
| Dean-Colomb et al. | Her2-positive breast cancer: herceptin and beyond | |
| Boku | HER2-positive gastric cancer | |
| Viloria-Petit et al. | Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies | |
| US20180155429A1 (en) | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody | |
| Kasper et al. | Targeted therapies in gastroesophageal cancer | |
| JP2021524744A (ja) | 分子遺伝子シグネチャーとその使用方法 | |
| JP2022060489A (ja) | ｃ－ＭＡＦの状態に基づく乳がんの治療的処置 | |
| JP2018538274A5 (cg-RX-API-DMAC7.html) | ||
| JP2017501137A5 (cg-RX-API-DMAC7.html) | ||
| JP2018508183A (ja) | 化学療法耐性癌を治療及び診断する組成物及び方法 | |
| KR20160048196A (ko) | 교모세포종의 치료를 위한 진단 방법 및 조성물 | |
| JP2020516253A5 (cg-RX-API-DMAC7.html) | ||
| JP2017517507A5 (cg-RX-API-DMAC7.html) | ||
| Bonello et al. | Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| Shibata et al. | Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells | |
| JP2019501973A5 (cg-RX-API-DMAC7.html) | ||
| JP2018516244A5 (cg-RX-API-DMAC7.html) | ||
| Majeed et al. | Gastric carcinoma: recent trends in diagnostic biomarkers and molecular targeted therapies | |
| JP2020522512A5 (cg-RX-API-DMAC7.html) | ||
| JP2016515141A5 (cg-RX-API-DMAC7.html) |